# A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)

> **NCT04105335** · PHASE1 · COMPLETED · sponsor: **Mina Alpha Limited** · enrollment: 50 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** MTL-CEBPA
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04105335
- **Lead sponsor:** Mina Alpha Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-13
- **Primary completion:** 2025-01-25
- **Final completion:** 2025-01-25
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04105335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04105335, "A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04105335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*